PMID- 29063221
OWN - NLM
STAT- MEDLINE
DCOM- 20180827
LR  - 20240313
IS  - 1875-8312 (Electronic)
IS  - 1569-5794 (Print)
IS  - 1569-5794 (Linking)
VI  - 34
IP  - 1
DP  - 2018 Jan
TI  - High T2-weighted signal intensity for risk prediction of sudden cardiac death in 
      hypertrophic cardiomyopathy.
PG  - 113-120
LID - 10.1007/s10554-017-1252-6 [doi]
AB  - In search of improved risk stratification in hypertrophic cardiomyopathy (HCM), 
      CMR imaging has been implicated as a potential tool for prediction of sudden 
      cardiac death (SCD). In follow-up of the promising results with extensive late 
      gadolinium enhancement (LGE), high signal-intensity on T2-weighted imaging 
      (HighT2) has become subject of interest given its association with markers of 
      adverse disease progression, such as LGE, elevated troponin and non-sustained 
      ventricular tachycardia. In lack of follow-up cohorts, we initiated an 
      exploratory study on the association between HighT2 and the internationally 
      defined risk categories of SCD. In a cohort of 109 HCM patients from a 
      multicenter study on CMR imaging and biomarkers, we estimated the 5-year SCD risk 
      (HCM Risk-SCD model). Patients were categorized as low (< 4%), intermediate 
      (>/= 4-<6%) or high (>/= 6%) risk. In addition, risk categorization according to the 
      ACC/AHA guidelines was performed. HighT2 was present in 27% (29/109). Patients 
      with HighT2 were more often at an intermediate-high risk of SCD according to the 
      European (28 vs. 10%, p = .032) and American guidelines (41 vs. 18%, p = .010) 
      compared to those without HighT2. The estimated 5-year SCD risk of our cohort was 
      1.9% (IQR 1.3-2.9%), and projected SCD rates were higher in patients with than 
      without HighT2 (2.8 vs. 1.8%, p = .002). In conclusion, HCM patients with HighT2 
      were more likely to be intermediate-high risk, with projected SCD rates that were 
      1.5 fold higher than in patients without HighT2. These pilot findings call for 
      corroborative studies with more intermediate-high risk HCM patients and clinical 
      follow-up to assess whether HighT2 may have additional value to current risk 
      stratification.
FAU - Gommans, D H Frank
AU  - Gommans DHF
AD  - Department of Cardiology, Radboud University Medical Center, Nijmegen, The 
      Netherlands. frank.gommans@radboudumc.nl.
AD  - Department of Cardiology 616, Radboud University Medical Center, Geert 
      Grooteplein 10, P.O. Box 9101, 6525 GA, Nijmegen, The Netherlands. 
      frank.gommans@radboudumc.nl.
FAU - Cramer, G Etienne
AU  - Cramer GE
AD  - Department of Cardiology, Radboud University Medical Center, Nijmegen, The 
      Netherlands.
FAU - Bakker, Jeannette
AU  - Bakker J
AD  - Department of Radiology, Albert Schweitzer Hospital, Dordrecht, The Netherlands.
FAU - Dieker, Hendrik-Jan
AU  - Dieker HJ
AD  - Department of Cardiology, Radboud University Medical Center, Nijmegen, The 
      Netherlands.
FAU - Michels, Michelle
AU  - Michels M
AD  - Department of Cardiology, Erasmus Medical Center, Rotterdam, The Netherlands.
FAU - Fouraux, Michael A
AU  - Fouraux MA
AD  - Department of Clinical Chemistry, Albert Schweitzer Hospital, Dordrecht, The 
      Netherlands.
FAU - Marcelis, Carlo L M
AU  - Marcelis CLM
AD  - Department of Clinical Genetics, Radboud University Medical Center, Nijmegen, The 
      Netherlands.
FAU - Verheugt, Freek W A
AU  - Verheugt FWA
AD  - Department of Cardiology, Radboud University Medical Center, Nijmegen, The 
      Netherlands.
FAU - Timmermans, Janneke
AU  - Timmermans J
AD  - Department of Cardiology, Radboud University Medical Center, Nijmegen, The 
      Netherlands.
FAU - Brouwer, Marc A
AU  - Brouwer MA
AD  - Department of Cardiology, Radboud University Medical Center, Nijmegen, The 
      Netherlands.
FAU - Kofflard, Marcel J M
AU  - Kofflard MJM
AD  - Department of Cardiology, Albert Schweitzer Hospital, Dordrecht, The Netherlands.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20171023
PL  - United States
TA  - Int J Cardiovasc Imaging
JT  - The international journal of cardiovascular imaging
JID - 100969716
SB  - IM
MH  - Adult
MH  - Aged
MH  - Cardiomyopathy, Hypertrophic/complications/*diagnostic imaging/mortality
MH  - Death, Sudden, Cardiac/*etiology
MH  - Female
MH  - Humans
MH  - *Magnetic Resonance Imaging
MH  - Male
MH  - Middle Aged
MH  - Netherlands
MH  - Pilot Projects
MH  - Predictive Value of Tests
MH  - Prognosis
MH  - Risk Assessment
MH  - Risk Factors
MH  - Time Factors
PMC - PMC5797557
OTO - NOTNLM
OT  - Cardiovascular magnetic resonance imaging
OT  - Hypertrophic cardiomyopathy
OT  - Sudden cardiac death
COIS- The authors declare that they have no conflict of interests.
EDAT- 2017/10/25 06:00
MHDA- 2018/08/28 06:00
PMCR- 2017/10/23
CRDT- 2017/10/25 06:00
PHST- 2017/05/08 00:00 [received]
PHST- 2017/09/29 00:00 [accepted]
PHST- 2017/10/25 06:00 [pubmed]
PHST- 2018/08/28 06:00 [medline]
PHST- 2017/10/25 06:00 [entrez]
PHST- 2017/10/23 00:00 [pmc-release]
AID - 10.1007/s10554-017-1252-6 [pii]
AID - 1252 [pii]
AID - 10.1007/s10554-017-1252-6 [doi]
PST - ppublish
SO  - Int J Cardiovasc Imaging. 2018 Jan;34(1):113-120. doi: 10.1007/s10554-017-1252-6. 
      Epub 2017 Oct 23.